Mirum Pharmaceuticals Director Buys Shares Worth $4,301
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Insiders At Mirum Pharmaceuticals Sold US$623k In Stock, Alluding To Potential Weakness
Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $44
Express News | Mirum Pharmaceuticals Inc : Baird Raises Target Price to $44 From $39
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q2 Revenue $77.9M, Vs. Street Est of $75.2M
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q2 Loss $-0.52, Vs. Street Est of $-0.45
Express News | Mirum Pharmaceuticals Inc: Q2 Global Net Product Sales of $77.8 Mln, on Track to Achieve Full-Year Guidance of $310 to $320 Mln
Express News | Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Express News | Mirum Pharmaceuticals Q2 Basic EPS USD -0.52
Express News | Mirum Pharmaceuticals Q2 Operating Expenses USD 102.107 Million
Express News | Mirum Pharmaceuticals Q2 Product Sales USD 77.76 Million